BR0308071A - Inibidores da protéina farnesil transferase como agentes antitumores - Google Patents

Inibidores da protéina farnesil transferase como agentes antitumores

Info

Publication number
BR0308071A
BR0308071A BR0308071-4A BR0308071A BR0308071A BR 0308071 A BR0308071 A BR 0308071A BR 0308071 A BR0308071 A BR 0308071A BR 0308071 A BR0308071 A BR 0308071A
Authority
BR
Brazil
Prior art keywords
compounds
protein inhibitors
formula
farnesyl transferase
transferase protein
Prior art date
Application number
BR0308071-4A
Other languages
English (en)
Inventor
Hugh Y Zhu
F George Njoroge
Alan B Cooper
Timothy J Guzi
Dinanath F Rane
Keith P Minor
Ronald J Doll
Viyyoor Moopil Girijavallabhan
Bama Santhanam
Patrick A Pinto
Bancha Vibulbhan
Kartik M Keertikar
Carmen S Alvarez
John J Baldwin
Ge Li
Huang Chia-Yu
Ray A James
W Robert Bishop
James J-S Wang
Jagdish A Desai
Original Assignee
Schering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896 external-priority patent/US20030229099A1/en
Application filed by Schering Corp, Pharmacopeia Drug Discovery filed Critical Schering Corp
Publication of BR0308071A publication Critical patent/BR0308071A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"INIBIDORES DA PROTEìNA FARNESIL TRANSFERASE COMO AGENTES ANTITUMORES". São apresentados novos compostos tricíclicos representados pela fórmula (1.0) e um sal ou solvato farmaceuticamente aceitável destes. Os compostos são úteis para a inibição da proteína farnesil transferase. Também são apresentados composições farmacêuticas compreendendo os compostos de fórmula 1.0. Da mesma forma são apresentados métodos de tratamento de câncer usando os compostos de fórmula 1.0.
BR0308071-4A 2002-02-27 2003-02-25 Inibidores da protéina farnesil transferase como agentes antitumores BR0308071A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/085,896 US20030229099A1 (en) 2000-08-30 2002-02-27 Novel farnesyl protein transferase inhibitors as antitumor agents
US10/325,896 US7342016B2 (en) 2000-08-30 2002-12-19 Farnesyl protein transferase inhibitors as antitumor agents
PCT/US2003/005479 WO2003072549A1 (en) 2002-02-27 2003-02-25 Farnesyl protein transferase inhibitors as antitumor agents

Publications (1)

Publication Number Publication Date
BR0308071A true BR0308071A (pt) 2004-12-21

Family

ID=27767345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308071-4A BR0308071A (pt) 2002-02-27 2003-02-25 Inibidores da protéina farnesil transferase como agentes antitumores

Country Status (19)

Country Link
US (1) US7342016B2 (pt)
EP (1) EP1492772A1 (pt)
JP (1) JP2005525356A (pt)
KR (1) KR20040098004A (pt)
CN (1) CN100537542C (pt)
AR (1) AR039557A1 (pt)
AU (1) AU2003215389B2 (pt)
BR (1) BR0308071A (pt)
CA (1) CA2477328A1 (pt)
CO (1) CO5611194A2 (pt)
IL (1) IL163673A0 (pt)
MX (1) MXPA04008303A (pt)
NO (1) NO20044053L (pt)
NZ (1) NZ534809A (pt)
PE (1) PE20031038A1 (pt)
PL (1) PL372335A1 (pt)
RU (1) RU2004128465A (pt)
TW (1) TW200303867A (pt)
WO (1) WO2003072549A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
ES2317047T3 (es) * 2003-08-07 2009-04-16 Schering Corporation Nuevos inhibidores de la farnesil proteina transferasa como agentes antitumorales.
AU2005249494A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
CA2569887A1 (en) 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
CA2591123A1 (en) 2004-12-14 2006-06-22 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
MX2007007611A (es) * 2004-12-21 2007-09-04 Schering Corp Nuevos inhibidores de la farnesil protein-transferasa como agentes antitumorales.
CA2637572A1 (en) * 2006-01-19 2007-07-26 Schering Corporation Piperazine derivatives as farnesyl protein transferase inhibitors
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
TWI577695B (zh) * 2006-12-19 2017-04-11 建南德克公司 用於輔助及先導性輔助療法之血管內皮生長因子（ｖｅｇｆ）-特異性拮抗劑及早期腫瘤之治療
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
CN105777646A (zh) * 2016-04-08 2016-07-20 西南科技大学 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法
CN111454329A (zh) * 2020-04-07 2020-07-28 哈尔滨师范大学 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法
WO2023071601A1 (zh) * 2021-10-28 2023-05-04 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5393890A (en) 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
AU8854091A (en) 1990-10-10 1992-05-20 Schering Corporation Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
SK86198A3 (en) * 1995-12-22 1999-02-11 Schering Corp Tricyclic amides useful for inhibition of g-protein function and for treatment of proliferative diseases
CN1237176A (zh) * 1996-09-13 1999-12-01 先灵公司 用作fpt抑制剂的三环化合物
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
AU4801197A (en) 1996-09-13 1998-04-02 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors
US6071907A (en) 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
IL133389A0 (en) 1997-06-17 2001-04-30 Schering Corp Novel n-substituted urea inhibitors of farnesyl-protein transferase
CA2294347C (en) 1997-06-17 2008-01-29 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives for the inhibition of farnesyl protein transferase
PE86199A1 (es) 1997-06-17 1999-09-24 Schering Corp Sulfonamida inhibidor de la enzima farnesilo transferasa
HUP0003138A3 (en) 1997-06-17 2002-11-28 Schering Corp Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
US5925648A (en) 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
PL348293A1 (en) 1998-12-18 2002-05-20 Schering Corp Tricyclic farnesyl protein transferase inhibitors
TR200101754T2 (tr) 1998-12-18 2002-05-21 Schering Corporation Farnezil protein transferaz inhibitörleri
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
SI1255537T1 (sl) 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
AU2002346644A1 (en) * 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
ES2317047T3 (es) * 2003-08-07 2009-04-16 Schering Corporation Nuevos inhibidores de la farnesil proteina transferasa como agentes antitumorales.

Also Published As

Publication number Publication date
RU2004128465A (ru) 2005-09-27
AU2003215389A1 (en) 2003-09-09
JP2005525356A (ja) 2005-08-25
NO20044053L (no) 2004-11-26
AR039557A1 (es) 2005-02-23
US20040122018A1 (en) 2004-06-24
KR20040098004A (ko) 2004-11-18
CA2477328A1 (en) 2003-09-04
PE20031038A1 (es) 2004-01-10
NZ534809A (en) 2007-12-21
CN100537542C (zh) 2009-09-09
WO2003072549A1 (en) 2003-09-04
AU2003215389B2 (en) 2007-10-18
CO5611194A2 (es) 2006-02-28
PL372335A1 (en) 2005-07-11
US7342016B2 (en) 2008-03-11
TW200303867A (en) 2003-09-16
CN1630641A (zh) 2005-06-22
EP1492772A1 (en) 2005-01-05
MXPA04008303A (es) 2005-11-23
IL163673A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
BR0308071A (pt) Inibidores da protéina farnesil transferase como agentes antitumores
MXPA05007352A (es) Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion.
BR0312408A (pt) Inibidores de peptìdeo de ligação de proteìna smac a inibidor de apoptose de proteìnas (iap)
LTC1934174I2 (lt) Azetinidai kaip MEK inhibitoriai, skirti proliferacinių ligų gydymui
BR0206955A (pt) Ligantes de receptores de canabinóides
BRPI0407618A (pt) derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
TW200613243A (en) Novel compounds
SE0302192D0 (sv) Novel compounds
TWI268280B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
BRPI0413384A (pt) inibidores da proteìna farnesil transferase como agentes antitumores
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
BR0207846A (pt) Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
ATE238981T1 (de) Antitumorwirkstoffe
BR0314363A (pt) Indóis 2,4-substituìdos e seu uso como moduladores de 5-ht6
JOP20250076A1 (ar) طرق لعلاج السرطان باستخدام مشتقات أيزو كوينولين أو 6-آزا-كوينولين
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
BRPI0608216A2 (pt) agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo
MX2009002998A (es) Derivado de pirazolopirimidina.
EP1453506A4 (en) Topoisomerase GIFT FUNDS
ECSP078015A (es) 4-anilino-3-quinolinocarbonitrilos para el tratamiento de cáncer
WO2002098399A3 (en) Cancer treatment method and compositions comprising compounds of the ginger family

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.